GNS and Servier announce AI collaboration in multiple myeloma
GNS is the leader in the use of “Digital Twins”, Causal AI and simulation technology to discover novel drug targets. The Gemini Digital Twin models across oncology, auto-immune diseases, and neurology enable the simulation of disease progression and drug response at the individual patient level to mimic clinical trials in diverse patient cohorts.
“This collaboration furthers Servier’s goal to accelerate its drug discovery and clinical development efforts through AI and biosimulation and other digital initiatives,” said Claude Bertrand, Executive Vice President Research and Development at Servier. “We believe GNS’ Digital Twin and unique causal AI models will help our research and early development group improve our understanding of multiple myeloma disease biology and, ultimately, transform our drug discovery and clinical development process”.
The collaboration will address key questions about how multiple myeloma progresses in different patient subpopulations, including discovering what are the most synergistic pathways for new combination therapies and will help Servier gain insights that can advance their clinical development efforts.
Did you know?
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer. Bone marrow is the spongy tissue at the centre of some bones that produces the body’s blood cells. It’s called multiple myeloma as the cancer often affects several areas of the body, such as the spine, skull, pelvis and ribs.